US · Healthcare · Biotechnology
EPS came in at -0.52 against a street estimate of -0.48 — a miss of 8.3%.
Analysts rate NewAmsterdam Pharma Company N.V. Ordinary Shares a strong buy (15 buy, 1 hold, 0 sell out of 16) with an average price target of $49.93.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 15.13% |
| Capital World Investors | 10.23% |
| FMR Inc | 8.65% |
| RA Capital Management, LLC | 7.99% |
| FCPM III SERVICES BV | 7.10% |
| Deerfield Management Co | 3.57% |
| Viking Global Investors LP | 3.52% |
| Bain Capital Life Sciences Investors, LLC | 3.18% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 HEADLINE NUMBERS • NewAmsterdam Pharma announced dosing of the first patient in SPINOZA, a Phase 2b clinical trial of obicetrapib in individuals with | 2026-09-29 |
| Company announcement · Q3 2026 NEWAMSTERDAM PHARMA COMPANY N.V. - 8-K SUMMARY HEADLINE NUMBERS • European Commission granted marketing authorization for two drug formulations on S | 2026-09-21 |
| Board / officer change · Q3 2026 NEWAMSTERDAM PHARMA COMPANY N.V. – 8-K SUMMARY HEADLINE NUMBERS • New Principal Accounting Officer appointed: Robert W. Gunning, age 55, effective A | 2026-08-14 |
| Quarterly report · Q2 2026 NEWAMSTERDAM PHARMA COMPANY N.V. — FORM 10-Q SUMMARY For the quarterly period ended June 30, 2026 --- HEADLINE NUMBERS • Cash position: $424.2 mill | 2026-08-05 |
| Results announced · Q3 2026 NEWAMSTERDAM PHARMA - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $678.3 million (cash, cash equivalents, and marketable securities) | 2026-08-05 |
| Company announcement · Q3 2026 NEWAMSTERDAM PHARMA COMPANY N.V. — 8-K SUMMARY HEADLINE NUMBERS • Company: NewAmsterdam Pharma Company N.V., Netherlands-based pharmaceutical compan | 2026-07-24 |
| Board / officer change · Q3 2026 NEWAMSTERDAM PHARMA COMPANY N.V. – 8-K SUMMARY HEADLINE NUMBERS • No financial data provided in this 8-K filing • Document filed July 22, 2026, repo | 2026-07-22 |
| Quarterly report · Q1 2026 NEWAMSTERDAM PHARMA COMPANY N.V. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $457.6 million in cash and cash equivalents as of March 31 | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| European Commission grants marketing authorization for two obicetrapib products NewAmsterdam Pharma announced that the European Commission approved two cholesterol-lowering drugs: Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib combined with ezetimibe). These | 2026-09-21 |
| PREVAIL interim analysis planned for 4Q26 with results expected in 1Q27 NewAmsterdam Pharma, a clinical-stage biotech company, reported Q1 2026 results with strong progress on its lead drug obicetrapib, which treats high cholesterol in cardiovascular disease pat | 2026-05-07 |
| Regulatory approval decisions expected 2H26; Phase 3 trial data timelines provided NewAmsterdam Pharma reported full-year 2025 results for its lead drug obicetrapib, a cholesterol-lowering treatment for cardiovascular disease patients. Key highlights: The company's Marketi | 2026-02-18 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NewAmsterdam Pharma Company N.V. Ordinary Shares — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.